StockData
Cresco Labs Inc. logo

Cresco Labs Inc. (CRLBF) stock

CRLBFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 6, 2026Score 4/30
$0.58−0.02 (-3.13%)

Close on Oct 19, 2026Market cap –P/E –Yield –

Cresco Labs Inc. saw revenue fall 9.5% to $655.85M over fiscal 2025. Operating income fell 126.1% to -$27.99M, moving the operating margin from 14.8% to -4.3%. Free cash flow was $37.75M, down 66.6% from a year earlier.

Revenue
$655.85M
-9.5% vs. a year earlier
Operating income
-$27.99M
-126.1% vs. a year earlier
Free cash flow
$37.75M
-66.6% vs. a year earlier
EPS, diluted
-$0.38
FY2025

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025

Valuation

Market cap
–
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$655.85M
Net income
-$135.41M
EPS, diluted
-$0.38
Free cash flow
$37.75M

Trading

Previous close
$0.59
Open
$0.59
Day's range
$0.58 – $0.62
Volume
295,884
Average volume (20 days)
645,522

Market cap history

Month-end market cap since 2020, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodCRLBFS&P 500DifferenceCRLBF per yearS&P 500 per year
1 month-23.2%+0.6%−23.8 pts
3 months-23.2%+3.4%−26.6 pts
Year to date-53.2%+13.3%−66.5 pts
1 year-52.8%+16.6%−69.4 pts
3 years-65.3%+86.4%−151.6 pts-29.7%+23.1%
5 years-93.2%+81.9%−175.0 pts-41.5%+12.7%

Seven years at a glance

Fiscal years 2019 to 2025, USD

Revenue

$655.85M-9.5% YoY

Gross profit

$324.57M-10.9% YoY

Operating income

-$27.99M-126.1% YoY

Net income

-$135.41M

EPS, diluted

-$0.38

Free cash flow

$37.75M-66.6% YoY
Reported period

Press releases

Releases Cresco Labs filed with the SEC as exhibits to Form 8-K or 6-K

  1. UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
    6-K
  2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
    6-K
  3. Cresco Labs Reports Third Quarter 2026 Financial Results
    6-K
  4. Cresco Labs Announces Voting Results of Its Annual General and Special Meeting of Shareholders
    6-K
  5. 6-K exhibit EX-99.1
    6-K
  6. 6-K exhibit EX-99.1
    6-K
All press releases and earnings

About Cresco Labs

Medicinal Chemicals & Botanical Products

Cresco Labs Inc. is a cannabis company that cultivates, produces, and sells cannabis and non-cannabis products. The company operates through two primary segments, wholesale and dispensary, supplying its own brand portfolio alongside partner products to consumers and commercial clients. Its retail footprint serves adult-use customers as well as registered patients seeking medical cannabis products.

Company profile, executives and history

Cresco Labs stock: common questions

What is Cresco Labs's stock price?

CRLBF closed at $0.58 on Oct 19, 2026, down 3.13% on the day.

What is CRLBF's P/E ratio?

Cresco Labs lost money over fiscal 2025 (diluted EPS -$0.38), so it has no meaningful P/E ratio.

How much revenue does Cresco Labs make?

Cresco Labs reported revenue of $655.85M for fiscal 2025, down 9.5% from a year earlier.

Does Cresco Labs pay a dividend?

No. Cresco Labs has not paid a cash dividend over the last twelve months.

How has CRLBF stock performed over the past year?

Including dividends, CRLBF returned -52.8% over the past year, against +16.6% for the S&P 500.

Who are Cresco Labs's competitors?

Companies most similar to Cresco Labs by business, industry and size include CURLF, JUSH, AAWH, TRLV, CGC.

See a number that looks wrong?